$TRDA
Entrada Therapeutics, Inc. Stock $trda

$trda Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000168937523000019 Filed on March 06, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$25.26M	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.938M	$9.894M	$30.64M
YoY Change	23.39%	62.25%	101.56%
% of Gross Profit
Research & Development	$23.10M	$15.69M	$66.61M
YoY Change	46.98%	26.88%	85.41%
% of Gross Profit
Depreciation & Amortization	$500.0K	$525.0K	$1.900M
YoY Change	25.0%	44.23%	72.73%
% of Gross Profit
Operating Expenses	$31.04M	$25.58M	$97.25M
YoY Change	40.13%	38.56%	90.21%
Operating Profit	-$5.780M		-$97.25M
YoY Change	-73.91%		90.21%
Interest Expense	$2.657M	$950.0K	$2.632M
YoY Change	453.54%	7207.69%	-8590.32%
% of Operating Profit
Other Income/Expense, Net	$2.657M		$2.632M
YoY Change	453.54%		-8590.32%
Pretax Income	-$3.123M	-$24.63M	-$94.62M
YoY Change	-85.59%	33.51%	84.95%
Income Tax	$3.600M		$0.00
% Of Pretax Income
Net Earnings	-$6.674M	-$24.63M	-$94.62M
YoY Change	-69.2%	33.51%	84.95%
Net Earnings / Revenue	-26.42%
Basic Earnings Per Share	-$0.21		-$3.02
Diluted Earnings Per Share	-$0.21	-$0.79	-$3.02
COMMON SHARES
Basic Shares Outstanding	33.08M shares	31.41M shares	31.29M shares
Diluted Shares Outstanding	32.37M shares		31.29M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$411.6M	$188.7M	$188.7M
YoY Change	55.98%	-35.16%	-35.16%
Cash & Equivalents	$227.6M	$45.16M	$45.16M
Short-Term Investments	$184.0M	$143.6M	$143.6M
Other Short-Term Assets	$16.21M	$21.16M	$21.16M
YoY Change	83.96%	177.15%	177.15%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$434.1M	$209.9M	$209.9M
YoY Change	59.19%	-29.74%	-29.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.394M	$7.681M	$33.02M
YoY Change	30.53%	22.68%	427.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$13.84M	$5.210M	$9.160M
YoY Change	865.34%	497.48%	950.46%
Total Long-Term Assets	$41.43M	$42.18M	$42.18M
YoY Change	-5.81%	491.35%	491.35%
TOTAL ASSETS
Total Short-Term Assets	$434.1M	$209.9M	$209.9M
Total Long-Term Assets	$41.43M	$42.18M	$42.18M
Total Assets	$475.6M	$252.1M	$252.1M
YoY Change	50.16%	-17.58%	-17.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.474M	$5.990M	$5.990M
YoY Change	120.88%	748.44%	748.44%
Accrued Expenses	$11.68M	$7.576M	$15.98M
YoY Change	158.09%	25.99%	165.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$147.6M	$21.97M	$21.97M
YoY Change	856.79%	227.01%	227.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$98.36M	$17.53M	$17.53M
YoY Change	311.82%	4326.77%	4326.77%
Total Long-Term Liabilities	$98.36M	$17.53M	$17.53M
YoY Change	311.82%	4326.77%	4326.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$147.6M	$21.97M	$21.97M
Total Long-Term Liabilities	$98.36M	$17.53M	$17.53M
Total Liabilities	$246.0M	$39.50M	$39.50M
YoY Change	525.67%	455.19%	455.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$195.0M	-$188.3M
YoY Change	69.12%	101.03%
Common Stock	$3.000K	$3.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$229.6M	$212.6M	$212.6M
YoY Change
Total Liabilities & Shareholders Equity	$475.6M	$252.1M	$252.1M
YoY Change	50.16%	-17.58%	-17.58%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$6.674M	-$24.63M	-$94.62M
YoY Change	-69.2%	33.51%	84.95%
Depreciation, Depletion And Amortization	$500.0K	$525.0K	$1.900M
YoY Change	25.0%	44.23%	72.73%
Cash From Operating Activities	$203.4M	-$27.30M	-$93.79M
YoY Change	-1068.98%	32.92%	84.39%
INVESTING ACTIVITIES
Capital Expenditures	$1.668M	$708.0K	$2.887M
YoY Change	180.81%	-153.56%	-36.97%
Acquisitions
YoY Change
Other Investing Activities	-$38.78M	$19.50M	-$145.8M
YoY Change	-78.57%
Cash From Investing Activities	-$40.44M	$18.79M	-$148.7M
YoY Change	-77.72%	-1521.48%	3145.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$19.54M	358.0K	$479.0K
YoY Change	38972.0%	-99.81%	-99.84%
NET CHANGE
Cash From Operating Activities	$203.4M	-27.30M	-$93.79M
Cash From Investing Activities	-$40.44M	18.79M	-$148.7M
Cash From Financing Activities	$19.54M	358.0K	$479.0K
Net Change In Cash	$182.5M	-8.154M	-$242.0M
YoY Change	-190.13%	-104.83%	-196.01%
FREE CASH FLOW
Cash From Operating Activities	$203.4M	-$27.30M	-$93.79M
Capital Expenditures	$1.668M	$708.0K	$2.887M
Free Cash Flow	$201.7M	-$28.01M	-$96.67M
YoY Change	-1034.59%	45.75%	74.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001689375
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40969
CY2022	dei	Entity Registrant Name EntityRegistrantName	ENTRADA THERAPEUTICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3983399
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	6 Tide Street
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02210
CY2022	dei	City Area Code CityAreaCode	857
CY2022	dei	Local Phone Number LocalPhoneNumber	520-9158
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	TRDA
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	274400000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33076359	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45157000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	291064000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	143555000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	0	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21163000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7636000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	209875000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	298700000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7681000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6261000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3950000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	25340000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5210000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	872000	usd
CY2022Q4	us-gaap	Assets Assets	252056000	usd
CY2021Q4	us-gaap	Assets Assets	305833000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5990000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	706000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7576000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6013000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8406000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21972000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6719000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17530000	usd
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	396000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	39502000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	7115000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31448508	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31394767	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31336092	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31224336	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	402893000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	392384000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2057000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-188285000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93669000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	212554000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	298718000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	252056000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	305833000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	66609000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35926000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30639000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15201000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	97248000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	51127000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-97248000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-51127000	usd
CY2022	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	2632000	usd
CY2021	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	-31000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2632000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-31000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-94616000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-51158000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.02
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.16
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.16
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31293312	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31293312	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6267776	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6267776	shares
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2057000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2057000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-96673000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51158000	usd
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	85299885	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	81658000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-41490000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	420000	usd
CY2021	trda	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	53522099	shares
CY2021	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	115831000	usd
CY2021	trda	Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	138821984	shares
CY2021	trda	Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities	197489000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	197489000	usd
CY2020	trda	Temporary Equity Issuance Costs TemporaryEquityIssuanceCosts	18034000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	190691000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	410000	usd
CY2021	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	250000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2526000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-51158000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	298718000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	195000	usd
CY2022	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	135000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	284000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9895000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2057000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-94616000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	212554000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-94616000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-51158000	usd
CY2022	us-gaap	Depreciation Depreciation	1895000	usd
CY2021	us-gaap	Depreciation Depreciation	1117000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-74000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	9895000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2526000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-151000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14022000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6733000	usd
CY2022	trda	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-7651000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4338000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	331000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	5287000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-715000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1762000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3962000	usd
CY2022	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	usd
CY2021	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	396000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-7451000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-93786000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50862000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2887000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4580000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	221977000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	76214000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-148650000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4580000	usd
CY2022	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	115831000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	190691000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	195000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	410000	usd
CY2022	trda	Proceeds From Early Exercise Of Stock Options ProceedsFromEarlyExerciseOfStockOptions	0	usd
CY2021	trda	Proceeds From Early Exercise Of Stock Options ProceedsFromEarlyExerciseOfStockOptions	529000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	284000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	479000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	307461000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-241957000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-51200000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-188300000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	188700000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	252019000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	291064000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39045000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49107000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	291064000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	88000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	155000	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	197489000	usd
CY2022	trda	Vesting Of Options Early Exercised Subject To Repurchase VestingOfOptionsEarlyExercisedSubjectToRepurchase	135000	usd
CY2021	trda	Vesting Of Options Early Exercised Subject To Repurchase VestingOfOptionsEarlyExercisedSubjectToRepurchase	250000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	32991000	usd
CY2022	trda	Transfer Of Deposits For Equipment From Operating To Investing Cash Flows TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows	495000	usd
CY2021	trda	Transfer Of Deposits For Equipment From Operating To Investing Cash Flows TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-94600000	usd
CY2022Q4	trda	Proceeds From Collaborators And Issuance Of Common Stock ProceedsFromCollaboratorsAndIssuanceOfCommonStock	250000000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to accrual and prepayment of research and development expenses and stock-based compensation. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</span></div>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. The Company’s marketable securities primarily consist of corporate bonds and U.S. government agency securities and treasuries, and potentially subject the Company to concentrations of credit risk. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations</span></div>
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45157000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	291064000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3950000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49107000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	291064000	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022Q4	us-gaap	Litigation Reserve LitigationReserve	0	usd
CY2021Q4	us-gaap	Litigation Reserve LitigationReserve	0	usd
CY2022	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	Indemnification AgreementsIn the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations (CROs), business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited.
CY2022Q4	us-gaap	Cash Cash	300000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	142170000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	140237000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossNoncurrent	3442000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	3318000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	145612000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2057000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	143555000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	32	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	143600000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	position
CY2022	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	usd
CY2021Q4	us-gaap	Cash Cash	300000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10982000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7677000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3301000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1416000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7681000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6261000	usd
CY2022	us-gaap	Depreciation Depreciation	1900000	usd
CY2021	us-gaap	Depreciation Depreciation	1100000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5063000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4077000	usd
CY2022Q4	trda	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	1157000	usd
CY2021Q4	trda	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	1032000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	925000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	419000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	431000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	485000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7576000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6013000	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	trda	Number Of Votes Per Common Share NumberOfVotesPerCommonShare	1	vote
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8032687	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6583887	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9895000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2526000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9895000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2526000	usd
CY2022	trda	Stock Issued During Period Shares Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions	53741	shares
CY2021	trda	Stock Issued During Period Shares Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions	111756	shares
CY2022Q4	trda	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount	200000	usd
CY2021Q4	trda	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount	300000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.055
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.061
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.050
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.039
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.014
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.003
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.301
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.307
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	32148000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25124000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7679000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3237000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1142000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	761000	usd
CY2022Q4	trda	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	15747000	usd
CY2021Q4	trda	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	0	usd
CY2022Q4	trda	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	7031000	usd
CY2021Q4	trda	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1109000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	430000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	34000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	137000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	64890000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29689000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	298000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	261000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	6869000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	304000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	485000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7471000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	746000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57419000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28943000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	trda	Operating Loss Carryforwards Subject To Expiration OperatingLossCarryforwardsSubjectToExpiration	3200000	usd
CY2022Q4	trda	Operating Loss Carryforwards Limitation On Use Amount OperatingLossCarryforwardsLimitationOnUseAmount	116100000	usd
CY2022	trda	Operating Loss Carryforwards Limitation On Use Annual Taxable Income Deduction Threshold Percent OperatingLossCarryforwardsLimitationOnUseAnnualTaxableIncomeDeductionThresholdPercent	0.80
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	800000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8774000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2022	us-gaap	Lease Cost LeaseCost	8774000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	8574000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0381
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9219000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9494000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8650000	usd
CY2022Q4	trda	Lessee Operating Lease Liability To Be Paid Due After Year Three LesseeOperatingLeaseLiabilityToBePaidDueAfterYearThree	0	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	27363000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1427000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	25936000	usd
CY2022Q1	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1 LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1	P10Y
CY2022Q1	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Renewal Term1 LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1	P5Y
CY2022Q1	trda	Operating Leases Rental Expenses Initial Fixed Monthly Rental Payments First12 Months OperatingLeasesRentalExpensesInitialFixedMonthlyRentalPaymentsFirst12Months	500000	usd
CY2022Q1	trda	Number Of Square Feet In Lease Agreement NumberOfSquareFeetInLeaseAgreement	65000	sqft
CY2022Q1	trda	Operating Leases Rental Expenses Annual Increase OperatingLeasesRentalExpensesAnnualIncrease	0.03
CY2022	trda	Lessee Operating Lease Base Rent Due Following Commencement Date Term Of Contract LesseeOperatingLeaseBaseRentDueFollowingCommencementDateTermOfContract	P10M
CY2022Q1	trda	Tenant Improvements Allowance TenantImprovementsAllowance	19500000	usd
CY2022Q1	trda	Initial Fixed Rental Income Per Rentable Square Foot Of Premises Per Annum InitialFixedRentalIncomePerRentableSquareFootOfPremisesPerAnnum	240.00
CY2022Q1	trda	Operating Leases Additional Allowance OperatingLeasesAdditionalAllowance	1600000	usd
CY2022Q1	trda	Tenant Allowance Rentable Square Foot Of Premises Per Annum TenantAllowanceRentableSquareFootOfPremisesPerAnnum	20.00
CY2022Q1	trda	Interest Rate For Additional Improvements Allowance InterestRateForAdditionalImprovementsAllowance	0.08
CY2022	trda	Lessee Operating Lease Level Direct Reduction Basis Term LesseeOperatingLeaseLevelDirectReductionBasisTerm	P120M
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	4000000	usd
CY2022Q4	trda	Lessee Operating Lease Reimbursable Improvement Costs Incurred LesseeOperatingLeaseReimbursableImprovementCostsIncurred	21200000	usd
CY2022Q4	trda	Lessee Operating Lease Reimbursed Costs LesseeOperatingLeaseReimbursedCosts	9800000	usd
CY2022Q4	trda	Prepaid Rent Noncurrent PrepaidRentNoncurrent	4300000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Lease Not Yet Commenced Term Of Contract1 LessorOperatingLeaseLeaseNotYetCommencedTermOfContract1	P3Y
CY2022Q4	trda	Lessor Operating Lease Lese Not Yet Commenced Monthly Payments To Be Received LessorOperatingLeaseLeseNotYetCommencedMonthlyPaymentsToBeReceived	200000	usd
CY2022Q4	trda	Sublease Interest Rate Increase Per Annum Percent SubleaseInterestRateIncreasePerAnnumPercent	0.03
CY2022Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	500000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-94616000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-51158000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31293312	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31293312	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6267776	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6267776	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.02
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.16
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.16
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5546555	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3573626	shares
CY2022Q4	trda	Strategic Collaboration And License Agreement Term Of Contract StrategicCollaborationAndLicenseAgreementTermOfContract	P4Y

Files In Submission

Name	View Source	Status
0001689375-23-000019-index-headers.html	Edgar Link	pending
0001689375-23-000019-index.html	Edgar Link	pending
0001689375-23-000019.txt	Edgar Link	pending
0001689375-23-000019-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trda-20221231.htm	Edgar Link	pending
trda-20221231.xsd	Edgar Link	pending
trda-20221231x1016.htm	Edgar Link	pending
trda-20221231x1017.htm	Edgar Link	pending
trda-20221231xex231.htm	Edgar Link	pending
trda-20221231xex31d1.htm	Edgar Link	pending
trda-20221231xex31d2.htm	Edgar Link	pending
trda-20221231xex32d1.htm	Edgar Link	pending
trda-20221231_g1.jpg	Edgar Link	pending
trda-20221231_g10.jpg	Edgar Link	pending
trda-20221231_g11.jpg	Edgar Link	pending
trda-20221231_g12.jpg	Edgar Link	pending
trda-20221231_g13.jpg	Edgar Link	pending
trda-20221231_g14.jpg	Edgar Link	pending
trda-20221231_g15.jpg	Edgar Link	pending
trda-20221231_g16.jpg	Edgar Link	pending
trda-20221231_g17.jpg	Edgar Link	pending
trda-20221231_g18.jpg	Edgar Link	pending
trda-20221231_g19.jpg	Edgar Link	pending
trda-20221231_g2.jpg	Edgar Link	pending
trda-20221231_g20.jpg	Edgar Link	pending
trda-20221231_g21.jpg	Edgar Link	pending
trda-20221231_g22.jpg	Edgar Link	pending
trda-20221231_g23.jpg	Edgar Link	pending
trda-20221231_g24.jpg	Edgar Link	pending
trda-20221231_g25.jpg	Edgar Link	pending
trda-20221231_g26.jpg	Edgar Link	pending
trda-20221231_g27.jpg	Edgar Link	pending
trda-20221231_g28.jpg	Edgar Link	pending
trda-20221231_g29.jpg	Edgar Link	pending
trda-20221231_g3.jpg	Edgar Link	pending
trda-20221231_g30.jpg	Edgar Link	pending
trda-20221231_g31.jpg	Edgar Link	pending
trda-20221231_g32.jpg	Edgar Link	pending
trda-20221231_g33.jpg	Edgar Link	pending
trda-20221231_g34.jpg	Edgar Link	pending
trda-20221231_g35.jpg	Edgar Link	pending
trda-20221231_g36.jpg	Edgar Link	pending
trda-20221231_g37.jpg	Edgar Link	pending
trda-20221231_def.xml	Edgar Link	unprocessable
trda-20221231_g38.jpg	Edgar Link	pending
trda-20221231_g39.jpg	Edgar Link	pending
trda-20221231_g4.jpg	Edgar Link	pending
trda-20221231_g5.jpg	Edgar Link	pending
trda-20221231_g6.jpg	Edgar Link	pending
trda-20221231_g7.jpg	Edgar Link	pending
trda-20221231_g8.jpg	Edgar Link	pending
trda-20221231_g9.jpg	Edgar Link	pending
trda_20221231xexx21x1.htm	Edgar Link	pending
trda-20221231_pre.xml	Edgar Link	unprocessable
trda-20221231_htm.xml	Edgar Link	completed
trda-20221231_cal.xml	Edgar Link	unprocessable
trda-20221231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TRDA
Entrada Therapeutics, Inc. Stock $trda

2023 Q1 Form 10-K Financial Statement

#000168937523000019 Filed on March 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRDA Entrada Therapeutics, Inc. Stock $trda

2023 Q1 Form 10-K Financial Statement

#000168937523000019 Filed on March 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRDA
Entrada Therapeutics, Inc. Stock $trda